Skip to main content
. 2017 Jul 21;96(29):e7605. doi: 10.1097/MD.0000000000007605

Figure 3.

Figure 3

Progression-free survival (A) and overall survival (B) of ovarian cancer patients in the metformin group and the discontinued group.